Tenatumomab I 131Alternative Names: 131I-Tenatumomab; 131Iodine-Tenatumomab; I131 anti-Tenascin monoclonal antibody; Tenatumomab/ST2146
Latest Information Update: 24 Nov 2015
At a glance
- Originator sigma-tau SpA
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Immunomodulators; Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 01 Nov 2015 Phase-I clinical trials in Cancer (Second-line therapy or greater, In adults, In the elderly, Late-stage disease) in France and Italy (IV) (NCT02602067)